Breaking Down Barriers: FDA Reverses Stance on Hormone Therapy for Menopause Symptoms
The U.S. Food and Drug Administration (FDA) has made a significant decision to remove the “black box” warning labels from numerous hormone therapy drugs used to treat menopause and perimenopause symptoms. This change is expected to encourage more women to seek treatment, as it marks a major shift in the FDA’s stance on hormone replacement therapy (HRT). According to FDA Commissioner Dr. Marty Makary, this move puts an end to a “fear machine” that has been in place for decades, which he describes as an “American tragedy.”
Dr. Makary emphasized that, with the exception of vaccines and antibiotics, no medication has the potential to improve women’s health on a population level more than hormone replacement therapy. He cited studies showing that menopause hormone therapy can reduce the risk of heart attacks, which is the leading cause of death in women. The products affected by this change include medications containing both estrogen and progesterone, systemic estrogen, and topical estrogen.
The Science Behind the Change
The “black box” warning labels were initially based on research from the Women’s Health Initiative study in 2002, which many experts now consider flawed. The study’s data focused on older women, overstating the risks of breast cancer. However, more recent studies have demonstrated that the benefits of hormone therapy outweigh the risks for many women, particularly when started in the early years of menopause, before the age of 60.
Dr. Makary highlighted the importance of having a nuanced understanding of the benefits and risks associated with hormone therapy. He stated, “We want to put that fear machine in its proper context and let people know that there are tremendous long-term health benefits.” These benefits include lowering the risk of cognitive decline, Alzheimer’s, and osteoporosis, a major factor in hip fractures.
Menopause and Hormone Therapy: What You Need to Know
Menopause typically occurs in a woman’s late 40s or early 50s, when the ovaries produce less estrogen and menstruation stops. Perimenopause refers to the transitional years leading up to menopause. Hormone therapy can help alleviate debilitating symptoms such as hot flashes, insomnia, night sweats, mood swings, joint pain, and weight gain.
Dr. Makary emphasized the significance of starting hormone replacement therapy within 10 years of the onset of menopause or perimenopause, and generally not starting it after age 60. He encouraged women to discuss their options with their doctor, stating, “We want people to have the right information… and part of that is addressing this fear machine that has been going on for 23 years.”
Non-Hormonal Therapy Treatments
While hormone therapy is the most effective treatment for hot flashes and night sweats, it may not be suitable for everyone, especially women with a history of breast cancer. The FDA recently approved a new, non-hormonal option called Lynkuet, which directly targets the brain pathways involved in body temperature control.
Despite the commonality of menopause, research funding has been limited, and medical education on the topic has been lacking. However, with more women in the medical field, this is starting to change. Dr. Makary noted, “It’s been a male-dominated culture in the medical establishment, historically. Now, roughly half of our medical students are women, and that’s a trend nationwide.”
For more information on this topic, visit Here
Image Source: www.cbsnews.com
